ArticleBMC pulmonary medicine2026

Efficacy, safety, and exploratory biomarker analysis of rechallenge with immune checkpoint inhibitors combined with anlotinib in previously treated advanced non-small cell lung cancer.

Li Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.